Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

Prognostic implications of admission inflammatory profile in acute ischemic neurological events

“…We conclude that an increased admission inflammatory response in patients with an acute ischemic neurological event might be associated with a less favorable outcome. The determination of inflammatory disease activity is relevant because of the presence of simple therapeutic interventions that might be relevant for the down‐regulation of both CRP concentration (17) and erythrocyte aggregability (18).…”

Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes

“…Ultimately, the best timing of statin initiation and a firm estimate of shortterm and long-term effects after early initiation await the results of ongoing, adequately powered, randomized clinical trials. Nonlipid effects of statins, such as anti-inflammatory, antiplatelet, and antithrombotic properties, [16][17][18][19][20][21][22][23][24][25][26][27][28] and improvements in endothelial function 16,19,[29][30][31][32] might confer an advantage early after experiencing an ACS event. However, the immediacy of these effects and their translation to clinical outcome has not been proved; many have only been shown after several weeks to months of therapy.…”

C‐reactive protein lowering with rosuvastatin in the METEOR study

“…In addition to established risk factors, inflammation is of critical importance in the pathogenesis of atherosclerosis [2, 3]. An elevated level of C‐reactive protein (CRP), an inflammatory biomarker, is a strong predictor for future cardiovascular events [4, 5], even in the absence of hyperlipidaemia [6–11]. Furthermore, CRP has been suggested to be an even stronger predictor of cardiovascular events than LDL‐C [12].…”

“…In addition, reduction in CRP combined with LDL‐C reduction by statin therapy may significantly contribute to the reduction of cardiovascular events [13–17]. Some studies found very modest relations between LDL‐C lowering and reduction in CRP levels associated with statin treatment, whereas others could not confirm those findings [6, 7, 9, 11, 12, 16–24]. In two recent meta‐analyses [25, 26] strong positive relations between changes in LDL‐C and CRP were reported, and the authors suggested that the CRP change was secondary to LDL‐C lowering.…”